ADRB3 and heart failure: In addition, the fact that β3-AR agonism causes angiogenesis and vasodilation in the ischemic heart [14,71] led to new pilot clinical trials assessing β3-AR agonists as promising therapeutic targets for the treatment of heart failure [12].